Table 1 Characteristics of the included randomized controlled trials in network meta-analysis
Authors, year | Country | Study name, design | Experiment group regimens | Control group regimens | Samples (E/C) | Main outcomes |
|---|---|---|---|---|---|---|
Craft et al. 2009 [22] | UK | EOI(80861), RCT | MTX 8 g/m2 DOX 25 mg/m2 daily times 3, CDP 100 mg/m2 24-h infusion | DOX 25 mg/m2 daily times 3, CDP 100 mg/m2 24-h infusion | 191/197 | OS, PFS, severe AEs |
Whelan et al. 2012 [24] | UK | EOI(80931), RCT | MTX 8 g/m2 DOX 75 mg/m2 CDP 100 mg/m2 every 3 weeks | DOX 75 mg/m2 CDP 100 mg/m2 every 3 weeks, | 90/89 | OS, PFS, severe AEs |
Ferrari et al. 2012 [23] | Italy | ISG/OS-1, RCT | MTX 12 g/m2 DOX 75 mg/m2 CDP 120 mg/m2 IFO 10 g/m2every 3 weeks | MTX 12 g/m2 DOX 75 mg/m2 CDP 120 mg/m2 every 3 weeks, | 123/123 | OS, PFS, severe AEs |
Bramwell et al.1997 [20] | Canada | RCT | MTX 8 g/m2 DOX 25 mg/m2 CDP 100 mg/m2 every 3 weeks | DOX 25 mg/m2 CDP 100 mg/m2 every 3 weeks, | 13/24 | OS, PFS, severe AEs |
Link et al. 1991 [18] | USA | MIOS, RCT | MTX 12 g/m2 DOX 75 mg/m2 CDP 120 mg/m2 IFO 10 g/m2every 3 weeks | MTX 12 g/m2 DOX 75 mg/m2 CDP 120 mg/m2 every 3 weeks | 18/18 | OS, PFS, severe AEs |
Bramwell et al. 1992 [19] | Canada | RCT | MTX 8 g/m2 DOX 25 mg/m2 CDP 100 mg/m2 every 3 weeks | DOX 25 mg/m2 CDP 100 mg/m2 every 3 weeks | 152/155 | OS, PFS, severe AEs |
Meyers et al. 2005 [21] | USA | CCG-7921, RCT | MTX 12 g/m2 DOX 75 mg/m2 CDP 120 mg/m2 IFO 9 g/m2every 3 weeks | MTX 12 g/m2 DOX 75 mg/m2 CDP 120 mg/m2 every 3 weeks | 167/172 | OS, PFS, severe AEs |